Muromonab-CD3 (Muromonab CD3)

Subscribe to Selected New Research on Muromonab-CD3

665 relevant articles (30 outcomes, 37 trials/studies) found for this Drug

Description: Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti). This biochemically purified IMMUNOGLOBULIN G is obtained through the fusion of mouse myeloma cells to lymphocytes from immunized animals to produce hybridomas that secrete specific antibodies to the T3 (CD3) antigens of human T-lymphocytes. It is often used as an IMMUNOSUPPRESSIVE AGENTS in TRANSPLANTATION.

Also Known As:

Muromonab CD3; OKT3; Cilag Brand of Muromonab-CD3; Janssen Brand of Muromonab-CD3; Ortho Brand of Muromonab-CD3; Orthoclone OKT3; Cilag Brand of Muromonab CD3; Janssen Brand of Muromonab CD3; Ortho Brand of Muromonab CD3; Monoclonal Antibody OKT3

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Globulins: 305

Serum Globulins: 74

Immunoglobulins: 20136

Antibodies: 77322

Monoclonal Antibodies: 16025

Muromonab-CD3: 665

hOKT3gamma1(Ala-Ala): 1

hOKT3 gamma4

monoclonal antibody huOKT3(Ala-Ala)

Immunoglobulin Isotypes: 348

Immunoglobulin G: 31640

Muromonab-CD3: 665

hOKT3gamma1(Ala-Ala): 1

hOKT3 gamma4

monoclonal antibody huOKT3(Ala-Ala)

Experts

1.	Beelen, Dietrich W: 1 article (12/2006)
2.	Rebmann, Vera: 1 article (12/2006)
3.	Ottinger, Hellmut D: 1 article (12/2006)
4.	Trenschel, Rudolf: 1 article (12/2006)
5.	Elmaagacli, Ahmet H: 1 article (12/2006)
6.	Lindemann, Monika: 1 article (12/2006)
7.	Grosse-Wilde, Hans: 1 article (12/2006)
8.	Cooper, M: 1 article (09/2006)
9.	Benekli, M: 1 article (09/2006)
10.	Stewart, C: 1 article (09/2006)

Related Diseases

1.	Infection 02/01/2005 - "Induction therapy with RATG (group V) was associated with significantly improved survival and freedom from acute rejection, BOS, and infection when compared to OKT3 induction therapy (group IV). " 02/01/2005 - "CONCLUSIONS: An earlier impression that RATG is superior to OKT3 induction therapy has borne true in terms of overall survival and incidence of BOS, acute rejection and infection rates. " 11/01/2009 - "However, injection of human liver-derived lymphocytes treated with IL-2/OKT3 completely prevented HCV infection. " 08/01/2001 - "The linearized rate (events/100 patient days) of all infections at 3 months was 1.55 +/- 0.28 for RATG group 1 and 2.19 +/- 0.27 for OKT3 group 1 (P = NS). " 04/01/1999 - "After exposure of patients to OKT3 an increased incidence of infections and malignancies has been reported. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 12/07/2006 - "CONCLUSION: This study identifies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confirms the prognostic value of tumor differentiation." 05/01/1999 - "A previous clinical Phase I trial examined OKT3 as an immunomodulator for the treatment of cancer. " 12/01/2002 - "The cytolytic efficiency of this antibody was comparable to that of a previously described bsAb, HEA125 x OKT3, targeting preactivated T lymphocytes against Ep-CAM-carrying tumor cells. " 03/01/2002 - "OKT3 use and rejection did not show significance in tumor development. " 06/01/2000 - "In conclusion, specific tumor cell lysis by PBSCs can be obtained in vitro by OKT3 activation and BIS-1 retargeting of T cells, without affecting HCF. " Order ALL the reference details at left...
3.	Delayed Graft Function 09/01/1992 - "Indirect evidence exists that a prophylactic course of OKT3 may be beneficial in immunologically high-risk patients and in patients with delayed graft function. " 02/01/1990 - "Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function." 10/01/1991 - "Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management." 02/01/1990 - "We conclude that OKT3 induction provides superior results over CsA induction at doses given in renal allograft recipients with delayed graft function without a significant increase in morbidity or mortality and permits the reuse of OKT3 for treatment of rejection in most cases." 11/01/1989 - "OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function." Order ALL the reference details at left...
4.	Pulmonary Edema 02/01/2004 - "OBJECTIVES: The use of OKT3 for treatment of advanced high-grade acute rejection episodes eventually can result in cytokine release and consecutive pulmonary edema. " 01/01/1994 - "Furthermore, the occurrence of pulmonary edema was directly related to OKT3 administration in 7 OKT3 patients (41%), whereas only 20 cases (24%) occurred in the extant OLT patients (p < 0.001). " 12/01/1995 - "Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction." 04/01/1993 - "Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction." 01/01/1991 - "Orthoclone OKT3 has been described to have significant adverse effects on the cardiovascular system, including pulmonary edema, angina, dysrhythmias, hypertension, and hypotension, usually following the first or second doses of the drug. " Order ALL the reference details at left...
5.	Melanoma (Melanoma, Malignant) 01/01/1990 - "Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3." 08/01/1993 - "In the 16 patients with melanoma who received OKT3 plus IL-2, there was a single objective response (complete response). " 04/01/1983 - "Functional T-cell subpopulations have been evaluated in the peripheral blood of 124 melanoma patients (71 non-metastatic and 53 metastatic) using monoclonal antibodies: OKT3, OKT4, OKT8, every 2 months for 1 year. " 04/01/1995 - "A patient with renal cell cancer treated at the 600-micrograms/m2 OKT3 dose level experienced a 4-month partial remission, and two mixed responses were observed in a sarcoma and a melanoma patient treated at 100- and 400-micrograms/m2 OKT3 dose levels, respectively. " 08/01/1993 - "PATIENTS AND METHODS: We performed a phase IB trial of a murine monoclonal anti-CD3 antibody (OKT3) with high-dose IL-2 in patients with advanced melanoma and renal cell carcinoma. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Antilymphocyte Serum (Anti-Thymocyte Globulin)
3.	HLA-A Antigens (HLA-A)
4.	Cyclosporine (Ciclosporin)
5.	HLA-DR Antigens (HLA-DR)
6.	DNA (Deoxyribonucleic Acid)
7.	Immunoglobulin G (IgG)
8.	Steroids
9.	Tacrolimus (Prograf)
10.	Immunoglobulins (Immunoglobulin)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Transplantation (Transplant Recipients)
3.	Transplants (Transplant)
4.	Kidney Transplantation
5.	Aftercare (After-Treatment)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>